298 patents
Page 10 of 15
Utility
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
4 Feb 21
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
Filed: 15 Apr 20
Utility
Dosing Regimen for an Ido Inhibitor
4 Feb 21
The present disclosure relates to dosing regimens for treating cancer by administering epacadostat in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Michael Smith, Robert C. Newton, Sherry Owens
Filed: 31 Jul 20
Utility
Salts of an LSD1 Inhibitor
4 Feb 21
The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
Yongchun Pan, Wayne Han, Ganfeng Cao, William Frietze, Zhongjiang Jia, Vaqar Sharief, Jiacheng Zhou, Qun Li
Filed: 12 Jun 20
Utility
Cyclopropylamines As LSD1 Inhibitors
4 Feb 21
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Joel R. Courter, Chunhong He, Ding-Quan Qian, Bo Shen, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
Filed: 9 Jun 20
Utility
Cyclopropylamines As LSD1 Inhibitors
28 Jan 21
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
Filed: 1 May 20
Utility
Pyrazolyl Pyrimidinylamine Compounds As CDK2 Inhibitors
21 Jan 21
The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 4 Mar 20
Utility
Heterocyclic Compounds As Immunomodulators
21 Jan 21
Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
Filed: 5 Oct 20
Utility
Heterocyclic Compounds As Immunomodulators
21 Jan 21
Zhenwu Li, Liangxing Wu, Wenqing Yao
Filed: 25 Sep 20
Utility
Bicyclic Heterocycles As FGFR Inhibitors
14 Jan 21
Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
Filed: 8 Jul 20
Utility
Topical Formulation for a Jak Inhibitor
6 Jan 21
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 16 Sep 20
Utility
Heterocyclic Compounds As Immunomodulators
6 Jan 21
Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
Filed: 14 Sep 20
Utility
Indazole Compounds and Uses Thereof
6 Jan 21
Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
Filed: 20 Jul 20
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
30 Dec 20
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 9 Jun 20
Utility
Thiazolecarboxamides and Pyridinecarboxamide Compounds Useful As Pim Kinase Inhibitors
30 Dec 20
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use.
Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
Filed: 15 Sep 20
Utility
Heterocyclic Compounds As Immunomodulators
30 Dec 20
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Filed: 10 Sep 20
Utility
PIPERIDIN-4-YL Azetidine Derivatives As JAK1 Inhibitors
23 Dec 20
The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Taisheng Huang, Chu-Biao Xue
Filed: 18 May 20
Utility
Immunomodulator Compounds and Methods of Use
23 Dec 20
Compositions and methods for inducing PD-L1 internalization are disclosed.
Phillip C. Liu, Alla Volgina, Richard Wynn, Nina Zolotarjova, Liangxing Wu, Kaijiong Xiao, Song Mei, Liang Lu, Wenyu Zhu, Yingda Ye, Haisheng Wang, Ding-Quan Qian, Wenqing Yao
Filed: 31 Aug 20
Utility
Bicyclic Heterocycles As FGFR4 Inhibitors
23 Dec 20
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
Filed: 8 Jul 20
Utility
Sulfonylamide Compounds As CDK2 Inhibitors
23 Dec 20
The present application provides sulfonyl amide compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 26 Mar 20
Utility
PYRROLO[2,3-D]PYRIMIDINONE Compounds As CDK2 Inhibitors
16 Dec 20
The present application provides pyrrolo[2,3-d]pyrimidinone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao
Filed: 13 Feb 20